List of Illuccix drug patents

Illuccix is owned by Telix.

Illuccix contains Gallium Ga-68 Gozetotide.

Illuccix has a total of 1 drug patent out of which 0 drug patents have expired.

Illuccix was authorised for market use on 17 December, 2021.

Illuccix is available in powder;intravenous dosage forms.

Illuccix can be used as positron emission tomography (pet) of prostate-specific membrane antigen (psma) positive lesions in men with prostate cancer.

The generics of Illuccix are possible to be released after 28 July, 2035.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11027031 TELIX Kit for radiolabelling
Jul, 2035

(12 years from now)

Drugs and Companies using GALLIUM GA-68 GOZETOTIDE ingredient

Market Authorisation Date: 17 December, 2021

Treatment: Positron emission tomography (pet) of prostate-specific membrane antigen (psma) positive lesions in men with prostate cancer

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic